Generative AI for Antibody Design, Protein Optimization, and Biomarker Discovery

Converge Bio is a Boston and Tel Aviv-based startup that helps pharma and biotech companies develop drugs faster using generative AI. The company trains generative models on DNA, RNA, and protein sequences, then plugs them into pharma and biotech workflows to speed up drug development. Converge has rolled out three discrete AI systems: one for antibody design, one for protein yield optimization, and one for biomarker and target discovery. For antibody design, the system combines generative models to create novel antibodies, predictive models to filter those antibodies based on desired properties, and 3D interaction modeling. The company has completed over 40 programs with more than a dozen pharmaceutical and biotech customers across the U.S., Canada, Europe, and Israel. In one case study, Converge helped a partner boost protein yield by 4 to 4.5X. The company raised $25M Series A with participation from Bessemer and executives from Meta, OpenAI, and Wiz.